 | |
| Formerly | Exelixis Pharmaceuticals, Inc. (1994-2000) |
|---|---|
| Company type | Public |
| Industry | Biotechnology |
| Founded | November 1994 |
| Headquarters | Alameda, California, U.S. |
Key people | Stelios Papadopoulos, Ph.D. (chairman) Michael M. Morrissey, Ph.D. (president & CEO)[1] |
| Revenue |  US$ 1.435 Billion (2021)[2] |
| US$ 0.287 Billion (2021)[3] | |
| US$ 0.231 Billion (2021)[4] | |
| Total assets | US$ 2.61 Billion (2021)[5] |
| Total equity | US$ 2.211 Billion (2021)[6] |
Number of employees | 954 (2021)[7] |
| Website | exelixis |
| Footnotes / references [8] | |
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
- ^ "Exelixis Inc. Profile". MarketWatch.com. Retrieved January 6, 2020.
- ^ "Exelixis Revenue 2010-2022".
- ^ "Exelixis Operating Income 2010-2022".
- ^ "Exelixis Net Income 2010-2022".
- ^ "Exelixis Total Assets 2010-2022".
- ^ "Exelixis Share Holder Equity 2010-2022".
- ^ "Exelixis: Number of Employees 2010-2022".
- ^ "US SEC: Form 10-K Exelixis, Inc". U.S. Securities and Exchange Commission. Retrieved November 3, 2021.